1. Retinoic Acid Reduces Stem Cell–Like Features in Pancreatic Cancer Cells
   Marta Herreros-Villanueva et al, 2015, Pancreas CrossRef
2. Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
   Maho Takahashi et al, 2017, Molecular and Cellular Biology CrossRef
3. Pancreatic cancer stem cells and inflammation: milestones achieved and challenges ahead
   Loganayaki Periyasamy et al, 2024, Cancer Stem Cells and Signaling Pathways CrossRef
4. ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism
   Hanxun Yue et al, 2022, Frontiers in Oncology CrossRef
5. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway
   Zhen-Hua Wu et al, 2016, PLOS ONE CrossRef
6. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
   Kyu Sic You et al, 2021, Pharmaceuticals CrossRef
7. Anti-Cancer Stem-like Cell Compounds in Clinical Development – An Overview and Critical Appraisal
   Fabrizio Marcucci et al, 2016, Frontiers in Oncology CrossRef
8. Comparative analysis of NRF2-responsive gene expression in AcPC-1 pancreatic cancer cell line
   Yong Weon Yi et al, 2015, Genes & Genomics CrossRef
9. Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells
   Hong-Quan Duong et al, 2017, Antioxidants CrossRef
10. Aldehyde Dehydrogenase Genes as Prospective Actionable Targets in Acute Myeloid Leukemia
    Garrett M. Dancik et al, 2023, Genes CrossRef
11. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
    Julian Palzer et al, 2021, International Journal of Nanomedicine CrossRef
12. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)
    Jia Lin Er et al, 2018, Apoptosis CrossRef
13. Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells
    Giuliana Catara et al, 2021, Frontiers in Oncology CrossRef
14. Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer
    J. Löhr et al, 2014, Pharmaceutics CrossRef
15. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action
    Tobias Bartscht et al, 2015, Molecular Cancer CrossRef
16. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells
    Kyu Sic You et al, 2021, Cancers CrossRef
17. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy
    Xiaofei Zhou et al, 2023, Artificial Cells, Nanomedicine, and Biotechnology CrossRef
18. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells
    Ling Ma et al, 2019, Cancer Biology & Therapy CrossRef
19. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
    Niharika B. Mettu et al, 2019, Cancer Chemotherapy and Pharmacology CrossRef